Cargando…
Early use of imipenem/cilastatin and vancomycin followed by de-escalation versus conventional antimicrobials without de-escalation for patients with hospital-acquired pneumonia in a medical ICU: a randomized clinical trial
INTRODUCTION: Although early use of broad-spectrum antimicrobials in critically ill patients may increase antimicrobial adequacy, uncontrolled use of these agents may select for more-resistant organisms. This study investigated the effects of early use of broad-spectrum antimicrobials in critically...
Autores principales: | Kim, Jong Wook, Chung, Joowon, Choi, Sang-Ho, Jang, Hang Jea, Hong, Sang-Bum, Lim, Chae-Man, Koh, Younsuck |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3396273/ https://www.ncbi.nlm.nih.gov/pubmed/22336530 http://dx.doi.org/10.1186/cc11197 |
Ejemplares similares
-
Safety of antimicrobial de-escalation for culture-negative severe pneumonia
por: Byoung Soo, Kwon, et al.
Publicado: (2019) -
1951. Nephrotoxicity Associated With Imipenem/Cilastatin/Relebactam (IMI/REL) vs. Imipenem/Cilastatin Plus Colistin (IMI+CST) in Patients With Imipenem-Nonsusceptible (NS) Bacterial Infections
por: Brown, Michelle, et al.
Publicado: (2018) -
Cost–effectiveness of imipenem/cilastatin/relebactam for hospital-acquired and ventilator-associated bacterial pneumonia
por: Naik, Jaesh, et al.
Publicado: (2023) -
Imipenem-cilastatin-induced psychosis: a case report
por: Ninan, Jacob, et al.
Publicado: (2016) -
New evidence in severe pneumonia: imipenem/ cilastatin/relebactam
por: Girón, Rosa Mª, et al.
Publicado: (2022)